This content is machine translated Tirzepatide for type 2 diabetes Post-hoc analysis of the SURPASS studies The SURPASS study program investigated the efficacy and safety of the dual GIP/GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. An exploratory analysis of the Phase III SURPASS…
